Correction to: JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress (Cell Death and Disease (2014) 5 (e1484) DOI: 10.1038/cddis.2014.408);JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Kostecka, A ^a   Sznarkowska, A ^a   Meller, K ^a   Acedo, P ^b   Shi, Y ^b   Mohammad Sakil, H A ^b   Kawiak, A ^a   Lion, M ^c   Krolicka A ^a   Wilhelm, M ^b   Inga, A ^c   Zawacka Pankau, J ^a,b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF TRENTO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NQO1 PROTEIN; OXIDOREDUCTASE; PROTEASOME; PROTEIN; PROTEIN MDM2; PROTEIN P73; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SERINE; STRESS ACTIVATED PROTEIN KINASE; TAP73 PROTEIN; THREONINE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; WITHAFERIN A; ANTIOXIDANT; DNA BINDING PROTEIN; NFE2L2 PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73; WITHANOLIDE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; HUMAN; HUMAN CELL; LETHALITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEASOMAL STRESS; STRESS; ANIMAL; BIOLOGICAL MODEL; CELL PROLIFERATION; DRUG EFFECTS; GENE DELETION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGICAL STRESS; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; GENE DELETION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MODELS, BIOLOGICAL; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; NF-E2-RELATED FACTOR 2; NUCLEAR PROTEINS; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; WITHANOLIDES;

EID: 84928042220     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/s41419-018-0655-1     Document Type: Erratum

References (67)

1. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-591.
2. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-516.
3. Frantz S. The trouble with making combination drugs. Nat Rev Drug Discov 2006; 5: 881-882.
4. Ranjan P, Anathy V, Burch PM, Weirather K, Lambeth JD, Heintz NH. Redox-dependent expression of cyclin D1 and cell proliferation by Nox1 in mouse lung epithelial cells. Antioxid Redox Signal 2006; 8: 1447-1459.
5. Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 2012; 16: 1215-1228.
6. Boonstra J, Post JA.Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004; 337: 1-13.
7. Dickinson BC, Chang CJ. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat Chem Biol 2011; 7: 504-511.
8. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol 2011; 194: 7-15.
9. Ma Q. Advances in mechanisms of anti-oxidation. Discov Med 2014; 17: 121-130.
10. Rotblat B, Melino G, Knight RA. NRF2 and p53: Januses in cancer? Oncotarget 2012; 3: 1272-1283.
11. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013; 12: 931-947.
12. Bossy-Wetzel E, Talantova MV, Lee WD, Schölzke MN, Harrop A, Mathews E et al. Crosstalk between nitric oxide and zinc pathways to neuronal cell death involving mitochondrial dysfunction and p38-activated K+ channels. Neuron 2004; 41: 351-365.
13. Colavitti R, Finkel T. Reactive oxygen species as mediators of cellular senescence. IUBMB Life 2005; 57: 277-281.
14. Aiken CT, Kaake RM, Wang X, Huang L. Oxidative stress-mediated regulation of proteasome complexes. Mol Cell Proteomics 2011; 10(R110): 006924.
15. Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Beher D, Masters CL et al. Reactive oxygen species and Alzheimer's disease. Biochem Pharmacol 1997; 54: 533-539.
16. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001; 3: 323-327.
17. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426: 895-899.
18. Ding Q, Dimayuga E, Martin S, Bruce-Keller AJ, Nukala V, Cuervo AM et al. Characterization of chronic low-level proteasome inhibition on neural homeostasis. J Neurochem 2003; 86:489-497.
19. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schröter F et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010; 142: 613-624.
20. Asher G, Tsvetkov P, Kahana C, Shaul Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 2005; 19: 316-321.
21. D'Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 2011; 17: 1636-1640.
22. Vyas AR, Singh SV. Molecular targets and mechanisms of cancer prevention and treatment by withaferin A, a naturally occurring steroidal lactone. AAPS J 2014; 16: 1-10.
23. Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, Ruiz A et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 2004; 7: 115-122.
24. Yang H, Shi G, Dou QP. The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry". Mol Pharmacol 2007; 71:426-437.
25. Khan S, Rammeloo AW, Heikkila JJ. Withaferin A induces proteasome inhibition, endoplasmic reticulum stress, the heat shock response and acquisition of thermotolerance. PLoS One 2012; 7: e50547.
26. Khedgikar V, Kushwaha P, Gautam J, Verma A, Changkija B, Kumar A et al. Withaferin A: a proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone. Cell Death Dis 2013; 4: e778.
27. Oh JH, Kwon TK. Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int Immunopharmacol 2009; 9: 614-619.
28. Bargagna-Mohan P, Ravindranath PP, Mohan R. Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization. Invest Ophthalmol Vis Sci 2006; 47: 4138-4145.
29. Falsey RR, Marron MT, Gunaherath GM, Shirahatti N, Mahadevan D, Gunatilaka AA et al. Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol 2006; 2: 33-38.
30. Vanden Berghe W, Sabbe L, Kaileh M, Haegeman G, Heyninck K. Molecular insight in the multifunctional activities of Withaferin A. Biochem Pharmacol 2012; 84: 1282-1291.
31. Hoe KK, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014; 13: 217-236.
32. Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30: 3633-3639.
33. Maas AM, Bretz AC, Mack E, Stiewe T. Targeting p73 in cancer. Cancer Lett 2013; 332: 229-236.
34. Candi E, Agostini M, Melino G, Bernassola F. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Hum Mutat 2014; 35: 702-714.
35. D'Alessandro A, Marrocco C, Rinalducci S, Peschiaroli A, Timperio AM, Bongiorno-Borbone L et al. Analysis of TAp73-dependent signaling via omics technologies. J Proteome Res 2013; 12: 4207-4220.
36. Tomasini R, Tsuchihara K,Wilhelm M, Fujitani M, Rufini A, Cheung CC et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008;22: 2677-2691.
37. Rufini A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A et al. TAp73 depletion accelerates aging through metabolic dysregulation. Genes Dev 2012; 26:2009-2014.
38. Cai Y, Qiu S, Gao X, Gu SZ, Liu ZJ. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes. Apoptosis 2012; 17:777-783.
39. Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H et al. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell 2012; 21: 196-211.
40. Zawacka-Pankau J, Kostecka A, Sznarkowska A, Hedström E, Kawiak A. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach? Cell Cycle 2010; 9: 720-728.
41. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008; 27: 997-1003.
42. Bell HS, Dufes C, O'Prey J, Crighton D, Bergamaschi D, Lu X et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest 2007; 117:1008-1018.
43. Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 2008; 105: 6302-6307.
44. Sznarkowska A, Malenczyk K, Kadzinski L, Bielawski KP, Banecki B, Zawacka-Pankau J. Targeting of p53 and its homolog p73 by protoporphyrin IX. FEBS Lett 2011; 585:255-260.
45. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-1328.
46. Shi Y, Nikulenkov F, Zawacka-Pankau J, Li H, Gabdoulline R, Xu J et al. ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ 2014; 21: 612-623.
47. Hahm ER, Moura MB, Kelley EE, Van Houten B, Shiva S, Singh SV. Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS One 2011; 6: e23354.
48. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501.
49. Shelton P, Jaiswal AK. The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? FASEB J 2013; 27: 414-423.
50. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 806-809.
51. Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, Melino G et al. Ubiquitindependent degradation of p73 is inhibited by PML. J Exp Med 2004; 199: 1545-1557.
52. Conforti F, Sayan AE, Sreekumar R, Sayan BS. Regulation of p73 activity by posttranslational modifications. Cell Death Dis 2012; 3: e285.
53. Caputo F, Vegliante R, Ghibelli L. Redox modulation of the DNA damage response. Biochem Pharmacol 2012; 84: 1292-1306.
54. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13: 76-86.
55. Chen C, Yu R, Owuor ED, Kong AN. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res 2000; 23: 605-612.
56. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13: 83-96.
57. Andreotti V, Ciribilli Y, Monti P, Bisio A, Lion M, Jordan J et al. p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system. PLoS One 2011; 6: e20643.
58. Rossi M, Sayan AE, Terrinoni A, Melino G, Knight RA. Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology. Ann N YAcad Sci 2004; 1028: 143-149.
59. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV et al. p73 in cancer. Genes Cancer 2011; 2: 491-502.
60. Agostini M, Tucci P, Killick R, Candi E, Sayan BS, Rivetti di Val Cervo P et al. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci USA 2011; 108: 21093-21098.
61. Wong SW, Tiong KH, Kong WY, Yue YC, Chua CH, Lim JY et al. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat 2011; 128: 301-313.
62. Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 2014; 123: 706-716.
63. Alard A, Fabre B, Anesia R, Marboeuf C, Pierre P, Susini C et al. NAD(P)H quinoneoxydoreductase 1 protects eukaryotic translation initiation factor 4GI from degradation by the proteasome. Mol Cell Biol 2010; 30: 1097-1105.
64. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003; 9: 493-501.
65. Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P. A versatile tool for conditional gene expression and knockdown. Nat Methods 2006; 3: 109-116.
66. Hedström E, Eriksson S, Zawacka-Pankau J, Arnér ES, Selivanova G. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle 2009; 8: 3576-3583.
67. Kawiak A, Piosik J, Stasilojc G, Gwizdek-Wisniewska A, Marczak L, Stobiecki M et al. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol Appl Pharmacol 2007; 223: 267-276.